Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Profile

Thomas Flaig

Concepts (382)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Urinary Bladder Neoplasms
37
2024
196
9.280
 Why?
Prostatic Neoplasms
36
2022
913
5.910
 Why?
Kidney Neoplasms
23
2023
324
3.940
 Why?
Prostatic Neoplasms, Castration-Resistant
18
2021
40
3.840
 Why?
Antineoplastic Agents
28
2021
1875
3.540
 Why?
Antineoplastic Combined Chemotherapy Protocols
26
2022
1356
3.490
 Why?
Carcinoma, Renal Cell
18
2023
168
3.470
 Why?
Carcinoma, Transitional Cell
12
2024
53
3.290
 Why?
Androgen Antagonists
14
2020
69
2.620
 Why?
Pyrroles
7
2017
181
1.690
 Why?
Neoadjuvant Therapy
8
2024
305
1.680
 Why?
Indoles
7
2017
300
1.560
 Why?
Medical Oncology
5
2020
229
1.460
 Why?
Urologic Neoplasms
6
2023
24
1.420
 Why?
Neoplasm Metastasis
24
2021
521
1.380
 Why?
Abiraterone Acetate
9
2021
14
1.360
 Why?
Urothelium
3
2016
33
1.320
 Why?
Adenocarcinoma
7
2020
787
1.180
 Why?
Prednisone
14
2021
229
1.170
 Why?
Taxoids
7
2017
93
1.150
 Why?
Phenylurea Compounds
6
2016
81
1.140
 Why?
Neoplasm Staging
13
2023
1162
1.120
 Why?
Antineoplastic Agents, Hormonal
8
2017
138
1.110
 Why?
Mitoxantrone
5
2018
12
1.100
 Why?
Niacinamide
5
2016
63
1.050
 Why?
Prostate-Specific Antigen
11
2022
150
1.040
 Why?
Male
86
2023
55396
1.030
 Why?
Orchiectomy
4
2014
57
1.010
 Why?
Cisplatin
11
2024
262
0.970
 Why?
Humans
125
2024
114043
0.960
 Why?
Antibodies, Monoclonal, Humanized
8
2024
660
0.920
 Why?
Penile Neoplasms
1
2023
7
0.870
 Why?
Aged
52
2022
18969
0.850
 Why?
Phenylthiohydantoin
6
2021
40
0.810
 Why?
Carcinoma
2
2016
198
0.800
 Why?
Testicular Neoplasms
3
2023
96
0.790
 Why?
Treatment Outcome
28
2023
9049
0.760
 Why?
ErbB Receptors
6
2018
554
0.760
 Why?
Immunotherapy
5
2022
473
0.750
 Why?
Protein Kinase Inhibitors
6
2014
784
0.740
 Why?
Nitriles
10
2021
149
0.710
 Why?
Neoplasm Invasiveness
6
2024
438
0.710
 Why?
Aged, 80 and over
25
2021
6306
0.700
 Why?
Radiosurgery
4
2015
299
0.660
 Why?
Disease-Free Survival
12
2017
618
0.620
 Why?
Bone Neoplasms
3
2015
191
0.610
 Why?
Sulfonamides
2
2012
444
0.600
 Why?
Cystectomy
5
2024
32
0.590
 Why?
Middle Aged
41
2021
26605
0.590
 Why?
Viscera
2
2014
15
0.590
 Why?
Hematologic Diseases
2
2016
55
0.580
 Why?
Prostatectomy
5
2018
97
0.560
 Why?
Antineoplastic Agents, Immunological
2
2020
152
0.560
 Why?
Urinary Bladder
3
2023
161
0.550
 Why?
Benzamides
7
2021
168
0.550
 Why?
Practice Guidelines as Topic
3
2019
1381
0.550
 Why?
Erythrocytes, Abnormal
1
2016
11
0.550
 Why?
Liver Neoplasms
3
2017
504
0.540
 Why?
Prognosis
12
2023
3315
0.540
 Why?
Receptors, Androgen
2
2021
131
0.510
 Why?
Pancreatitis
1
2016
105
0.510
 Why?
Genomics
2
2018
633
0.510
 Why?
Silymarin
4
2013
194
0.470
 Why?
Leydig Cell Tumor
1
2014
8
0.460
 Why?
Epithelial-Mesenchymal Transition
2
2016
167
0.430
 Why?
Multicenter Studies as Topic
2
2021
249
0.420
 Why?
Chemotherapy, Adjuvant
7
2023
332
0.410
 Why?
Proto-Oncogene Proteins p21(ras)
1
2013
228
0.410
 Why?
Gene Expression Profiling
1
2018
1519
0.400
 Why?
Hypothyroidism
1
2012
65
0.400
 Why?
Carcinoma, Basal Cell
1
2013
66
0.390
 Why?
Administration, Intravesical
3
2022
14
0.390
 Why?
Sarcoma
1
2013
137
0.390
 Why?
Neoplasms, Germ Cell and Embryonal
2
2023
62
0.390
 Why?
Therapies, Investigational
1
2011
14
0.390
 Why?
Diethylstilbestrol
1
2011
8
0.380
 Why?
Angiomyolipoma
1
2011
17
0.380
 Why?
Antibodies, Monoclonal
5
2024
1257
0.380
 Why?
Receptors, Vascular Endothelial Growth Factor
2
2013
103
0.370
 Why?
Disease Progression
10
2021
2371
0.360
 Why?
Pyrazoles
2
2023
361
0.360
 Why?
Lung Neoplasms
5
2017
2159
0.360
 Why?
Leukemia, Myeloid, Acute
2
2008
533
0.360
 Why?
Neoplastic Cells, Circulating
1
2011
57
0.360
 Why?
Androstenes
4
2015
11
0.350
 Why?
Retrospective Studies
12
2024
12521
0.350
 Why?
Molecular Targeted Therapy
1
2013
347
0.350
 Why?
United States
10
2023
12137
0.340
 Why?
Adult
25
2021
30375
0.340
 Why?
Receptors, Fibroblast Growth Factor
1
2010
63
0.340
 Why?
Recombinant Fusion Proteins
1
2012
613
0.340
 Why?
Neoplasm Proteins
1
2013
385
0.340
 Why?
Kaplan-Meier Estimate
8
2016
813
0.340
 Why?
Tumor Suppressor Protein p53
1
2013
445
0.340
 Why?
Neoplasms, Multiple Primary
1
2010
52
0.330
 Why?
SEER Program
4
2023
195
0.330
 Why?
Antineoplastic Agents, Phytogenic
2
2010
181
0.330
 Why?
Neoplasm Recurrence, Local
4
2022
850
0.320
 Why?
Lymphatic Diseases
1
2009
17
0.320
 Why?
Neuroblastoma
1
2010
133
0.320
 Why?
Vascular Endothelial Growth Factors
1
2009
61
0.320
 Why?
Survival Rate
9
2021
1638
0.320
 Why?
Cystitis
1
2009
20
0.320
 Why?
Vascular Endothelial Growth Factor A
2
2019
496
0.320
 Why?
Double-Blind Method
12
2021
1656
0.310
 Why?
Female
26
2021
59325
0.310
 Why?
Androstadienes
3
2013
97
0.300
 Why?
Precision Medicine
1
2011
335
0.300
 Why?
Pneumatosis Cystoides Intestinalis
1
2008
18
0.300
 Why?
Intestinal Perforation
1
2008
39
0.300
 Why?
Clinical Trials as Topic
5
2018
926
0.300
 Why?
Pyrimidines
1
2011
374
0.300
 Why?
Deoxycytidine
3
2024
138
0.300
 Why?
Muscles
3
2024
320
0.300
 Why?
Carcinoma, Squamous Cell
1
2013
577
0.290
 Why?
Pancreatic Neoplasms
1
2014
721
0.290
 Why?
Testosterone
3
2021
341
0.290
 Why?
Survival Analysis
6
2021
1206
0.280
 Why?
BCG Vaccine
2
2018
18
0.280
 Why?
Androgen Receptor Antagonists
3
2021
30
0.270
 Why?
Combined Modality Therapy
9
2020
1117
0.270
 Why?
Cell Line, Tumor
7
2018
2698
0.270
 Why?
Nanotubes
2
2018
41
0.270
 Why?
Quinazolines
4
2019
240
0.260
 Why?
Neoplasm Grading
6
2018
241
0.260
 Why?
Carboplatin
1
2006
135
0.260
 Why?
Gold
2
2018
102
0.260
 Why?
Skin Neoplasms
1
2013
754
0.250
 Why?
Tumor Microenvironment
3
2023
428
0.250
 Why?
Lymphatic Metastasis
2
2018
275
0.250
 Why?
Gonadotropin-Releasing Hormone
2
2020
189
0.250
 Why?
Drug Resistance, Neoplasm
3
2018
636
0.250
 Why?
Biomarkers, Tumor
4
2023
1032
0.240
 Why?
Randomized Controlled Trials as Topic
3
2021
1204
0.240
 Why?
Societies, Medical
2
2018
655
0.230
 Why?
Radiotherapy, Adjuvant
2
2018
182
0.230
 Why?
Drug Synergism
3
2011
315
0.230
 Why?
Dexamethasone
1
2006
316
0.230
 Why?
Androstenols
3
2015
4
0.220
 Why?
Dose-Response Relationship, Drug
5
2013
1836
0.220
 Why?
Tosyl Compounds
4
2018
14
0.220
 Why?
Drug Administration Schedule
4
2021
714
0.210
 Why?
Gene Expression Regulation, Neoplastic
2
2021
1142
0.210
 Why?
Vitamin D
1
2006
340
0.210
 Why?
Steroid 17-alpha-Hydroxylase
2
2014
4
0.210
 Why?
Cell-Free Nucleic Acids
1
2023
26
0.210
 Why?
Anilides
4
2018
67
0.210
 Why?
Quality of Life
4
2024
2343
0.200
 Why?
Sleep Initiation and Maintenance Disorders
1
2024
119
0.200
 Why?
Retroperitoneal Space
1
2021
14
0.200
 Why?
Patient Reported Outcome Measures
2
2024
251
0.200
 Why?
Thiohydantoins
1
2021
2
0.190
 Why?
Indazoles
2
2012
57
0.190
 Why?
Tissue Extracts
2
2012
19
0.190
 Why?
Databases, Factual
2
2016
1125
0.190
 Why?
Kallikreins
2
2019
28
0.190
 Why?
Retreatment
1
2021
67
0.180
 Why?
Bone Marrow Transplantation
1
2002
237
0.180
 Why?
Tomography, X-Ray Computed
4
2014
2272
0.180
 Why?
Time Factors
5
2020
6077
0.170
 Why?
Genetic Heterogeneity
1
2020
47
0.170
 Why?
Phosphatidylcholines
2
2013
132
0.170
 Why?
Angiogenesis Inhibitors
2
2021
213
0.160
 Why?
In Situ Hybridization, Fluorescence
2
2011
308
0.160
 Why?
Yttrium
1
2018
5
0.160
 Why?
Cell Adhesion Molecules
1
2020
167
0.160
 Why?
Fluorides
1
2018
43
0.160
 Why?
Euterpe
1
2018
5
0.160
 Why?
Central Nervous System
1
2020
230
0.150
 Why?
Piperidines
2
2010
159
0.150
 Why?
Organ Sparing Treatments
1
2018
31
0.150
 Why?
Costimulatory and Inhibitory T-Cell Receptors
1
2018
7
0.150
 Why?
Lymph Node Excision
2
2021
140
0.150
 Why?
Congresses as Topic
2
2012
193
0.150
 Why?
Odds Ratio
1
2021
951
0.150
 Why?
Apoptosis
1
2007
2349
0.150
 Why?
Antioxidants
2
2013
529
0.150
 Why?
History, 21st Century
2
2015
160
0.150
 Why?
Tumor Escape
1
2018
35
0.150
 Why?
Cancer Vaccines
1
2019
137
0.150
 Why?
Genome
1
2020
270
0.150
 Why?
Neoplasm, Residual
2
2021
104
0.140
 Why?
Microscopy, Fluorescence
3
2018
393
0.140
 Why?
Proton Therapy
1
2017
10
0.140
 Why?
Blotting, Western
2
2010
1143
0.140
 Why?
Practice Patterns, Physicians'
2
2016
1175
0.140
 Why?
Biopsy
3
2018
1024
0.140
 Why?
Goserelin
3
2018
8
0.140
 Why?
Erythrocyte Indices
1
2016
27
0.140
 Why?
Plant Extracts
1
2018
154
0.140
 Why?
Aftercare
1
2018
186
0.140
 Why?
Oligopeptides
1
2018
234
0.130
 Why?
Dyslipidemias
1
2018
153
0.130
 Why?
Fatal Outcome
2
2008
281
0.130
 Why?
Watchful Waiting
1
2016
54
0.130
 Why?
Adverse Drug Reaction Reporting Systems
1
2016
68
0.130
 Why?
High-Throughput Nucleotide Sequencing
1
2018
437
0.130
 Why?
United States Food and Drug Administration
1
2016
172
0.130
 Why?
Prostate
2
2021
157
0.120
 Why?
Disease Management
1
2019
556
0.120
 Why?
Nanoparticles
1
2018
312
0.120
 Why?
Patient Selection
1
2018
629
0.120
 Why?
Soft Tissue Neoplasms
1
2015
89
0.120
 Why?
Radiation Tolerance
1
2015
92
0.120
 Why?
Insurance, Health
1
2016
243
0.120
 Why?
Ablation Techniques
1
2014
25
0.120
 Why?
Cytochrome P-450 Enzyme Inhibitors
1
2014
4
0.110
 Why?
Mitotic Index
1
2014
26
0.110
 Why?
Magnetic Resonance Imaging
3
2021
3039
0.110
 Why?
Neoplasms, Hormone-Dependent
1
2014
38
0.110
 Why?
Glucocorticoids
1
2018
526
0.110
 Why?
Hyperthermia, Induced
1
2014
66
0.110
 Why?
Neoplasms, Complex and Mixed
1
2013
7
0.110
 Why?
Carcinoma, Medullary
1
2013
14
0.110
 Why?
Receptor, ErbB-2
1
2016
300
0.110
 Why?
beta-Galactosidase
1
2013
62
0.110
 Why?
Breeding
1
2013
54
0.110
 Why?
Sirolimus
2
2014
181
0.110
 Why?
Geriatrics
1
2014
69
0.110
 Why?
Reproducibility of Results
2
2013
2764
0.110
 Why?
Brain Neoplasms
1
2021
966
0.110
 Why?
Interleukin-2
1
2014
413
0.110
 Why?
Staining and Labeling
1
2013
134
0.110
 Why?
Cell Proliferation
2
2012
2173
0.110
 Why?
Hyperplasia
1
2013
163
0.110
 Why?
Keratins
1
2013
176
0.110
 Why?
Urogenital Neoplasms
1
2012
5
0.100
 Why?
Tumor Stem Cell Assay
1
2012
33
0.100
 Why?
Population Surveillance
1
2015
385
0.100
 Why?
Nephrectomy
2
2013
149
0.100
 Why?
Organ Specificity
1
2013
266
0.100
 Why?
Adenoviridae
1
2013
184
0.100
 Why?
Integrases
1
2013
116
0.100
 Why?
Fluorescent Antibody Technique
1
2013
396
0.100
 Why?
Celecoxib
1
2012
38
0.100
 Why?
Thyroid Hormones
1
2012
53
0.100
 Why?
Quinolines
1
2013
129
0.100
 Why?
Thyroid Gland
1
2012
85
0.100
 Why?
RNA, Untranslated
1
2013
113
0.100
 Why?
Bone Diseases
1
2012
57
0.100
 Why?
Cross-Over Studies
3
2021
439
0.100
 Why?
Reoperation
1
2014
513
0.100
 Why?
Carcinoma, Hepatocellular
1
2013
210
0.090
 Why?
Imidazoles
1
2012
203
0.090
 Why?
Denosumab
1
2010
7
0.090
 Why?
PubMed
1
2010
10
0.090
 Why?
Animals
5
2016
31565
0.090
 Why?
RANK Ligand
1
2010
26
0.090
 Why?
Benzenesulfonates
1
2010
19
0.090
 Why?
Neoplasms
2
2022
2086
0.090
 Why?
Erlotinib Hydrochloride
1
2010
64
0.090
 Why?
Vimentin
1
2010
58
0.090
 Why?
Insulin-Like Growth Factor Binding Protein 3
1
2010
38
0.090
 Why?
Xenograft Model Antitumor Assays
1
2012
695
0.090
 Why?
Cell Separation
1
2011
290
0.090
 Why?
Hypertension
1
2018
1052
0.090
 Why?
Mesoderm
1
2010
138
0.080
 Why?
Cardiovascular Diseases
2
2018
1726
0.080
 Why?
Tumor Cells, Cultured
1
2011
845
0.080
 Why?
Cadherins
1
2010
175
0.080
 Why?
Carcinoma, Papillary
1
2009
74
0.080
 Why?
Age Factors
1
2016
2885
0.080
 Why?
Nephrolithiasis
1
2009
10
0.080
 Why?
Metaplasia
1
2009
54
0.080
 Why?
Gynecomastia
1
2008
4
0.080
 Why?
Risk Factors
5
2018
8614
0.080
 Why?
Chromatography, Liquid
1
2010
345
0.080
 Why?
Risk
1
2011
810
0.080
 Why?
Genotype
1
2013
1757
0.080
 Why?
Mice, Transgenic
1
2013
1947
0.080
 Why?
Drug Therapy, Combination
1
2011
949
0.080
 Why?
Proportional Hazards Models
3
2016
1078
0.070
 Why?
Tandem Mass Spectrometry
1
2010
410
0.070
 Why?
Insulin-Like Growth Factor I
1
2010
286
0.070
 Why?
Southwestern United States
1
2008
90
0.070
 Why?
Liver Failure, Acute
1
2008
58
0.070
 Why?
Hormone Replacement Therapy
1
2008
76
0.070
 Why?
Mediastinal Diseases
1
2007
9
0.070
 Why?
Carcinoid Tumor
1
2007
23
0.070
 Why?
Mice
2
2013
14841
0.070
 Why?
Pyridines
1
2010
419
0.070
 Why?
Glucuronides
1
2006
12
0.070
 Why?
Neoplasms, Second Primary
1
2008
92
0.070
 Why?
Spectrophotometry, Ultraviolet
1
2006
73
0.070
 Why?
Medical History Taking
1
2007
115
0.070
 Why?
Excipients
1
2006
49
0.070
 Why?
Liver Function Tests
1
2006
103
0.070
 Why?
Chemistry, Pharmaceutical
1
2006
98
0.070
 Why?
Syndrome
1
2007
330
0.070
 Why?
Antibiotics, Antineoplastic
1
2006
110
0.070
 Why?
Spectrometry, Mass, Electrospray Ionization
1
2006
161
0.060
 Why?
Pedigree
1
2007
460
0.060
 Why?
Sarcoidosis
1
2007
133
0.060
 Why?
Everolimus
2
2017
61
0.060
 Why?
Radiography
1
2008
803
0.060
 Why?
Signal Transduction
2
2016
4501
0.060
 Why?
Doxorubicin
1
2006
286
0.060
 Why?
Forecasting
1
2007
331
0.060
 Why?
Metabolic Syndrome
1
2008
320
0.060
 Why?
Biomarkers
2
2023
3397
0.060
 Why?
Epithelial Cells
1
2010
946
0.060
 Why?
Melanoma
1
2011
620
0.060
 Why?
Diagnosis, Differential
1
2009
1331
0.060
 Why?
DNA Damage
1
2007
351
0.060
 Why?
Gastrointestinal Diseases
1
2006
182
0.060
 Why?
Referral and Consultation
1
2009
632
0.060
 Why?
Radiotherapy
2
2015
175
0.060
 Why?
Carcinoma, Non-Small-Cell Lung
1
2012
959
0.060
 Why?
Young Adult
4
2021
10444
0.050
 Why?
Disease Models, Animal
1
2012
3498
0.050
 Why?
Follow-Up Studies
2
2015
4392
0.050
 Why?
Immunohistochemistry
2
2020
1624
0.050
 Why?
Maximum Tolerated Dose
2
2013
183
0.050
 Why?
Immune System Diseases
1
2002
32
0.050
 Why?
Steroid Synthesis Inhibitors
1
2021
1
0.050
 Why?
Proteomics
1
2007
815
0.050
 Why?
Mass Screening
1
2008
979
0.050
 Why?
Policy
1
2022
137
0.050
 Why?
Clinical Trials, Phase III as Topic
1
2021
82
0.050
 Why?
Prednisolone
1
2021
75
0.050
 Why?
Metabolic Diseases
1
2002
98
0.050
 Why?
Tumor Burden
1
2021
258
0.050
 Why?
Bevacizumab
1
2021
114
0.040
 Why?
Phosphatidylinositol 3-Kinases
1
2022
328
0.040
 Why?
Proto-Oncogene Proteins c-akt
1
2022
397
0.040
 Why?
Asymptomatic Diseases
1
2021
75
0.040
 Why?
TOR Serine-Threonine Kinases
1
2022
359
0.040
 Why?
Neovascularization, Pathologic
1
2021
280
0.040
 Why?
Hospitals
1
2023
581
0.040
 Why?
Ytterbium
1
2018
2
0.040
 Why?
HLA-A2 Antigen
1
2019
35
0.040
 Why?
Erbium
1
2018
5
0.040
 Why?
Estrogen Receptor alpha
1
2020
121
0.040
 Why?
Risk Assessment
1
2008
2958
0.040
 Why?
DNA Methylation
1
2023
493
0.040
 Why?
Drug-Related Side Effects and Adverse Reactions
1
2021
239
0.040
 Why?
Fruit and Vegetable Juices
1
2018
11
0.040
 Why?
Granulocyte-Macrophage Colony-Stimulating Factor
1
2019
140
0.040
 Why?
Luminescent Measurements
1
2018
74
0.040
 Why?
Pain
1
2024
701
0.040
 Why?
Lasers
1
2018
121
0.040
 Why?
Laparoscopy
1
2021
395
0.040
 Why?
National Cancer Institute (U.S.)
1
2017
40
0.030
 Why?
Antibodies
1
2018
365
0.030
 Why?
Risk Reduction Behavior
1
2018
200
0.030
 Why?
DNA
1
2023
1350
0.030
 Why?
Abdominal Neoplasms
1
2015
26
0.030
 Why?
Molecular Diagnostic Techniques
1
2016
92
0.030
 Why?
Thoracic Neoplasms
1
2015
31
0.030
 Why?
Placebos
1
2015
197
0.030
 Why?
Administration, Oral
1
2017
725
0.030
 Why?
Radiotherapy Planning, Computer-Assisted
1
2015
117
0.030
 Why?
Antihypertensive Agents
1
2018
428
0.030
 Why?
Nanoconjugates
1
2014
1
0.030
 Why?
Spectrophotometry, Atomic
1
2014
13
0.030
 Why?
Lipids
1
2018
564
0.030
 Why?
Platelet Aggregation Inhibitors
1
2018
395
0.030
 Why?
Radiotherapy, Intensity-Modulated
1
2015
124
0.030
 Why?
Smoking Cessation
1
2018
374
0.030
 Why?
Hydroxymethylglutaryl-CoA Reductase Inhibitors
1
2018
373
0.030
 Why?
Benchmarking
1
2015
161
0.030
 Why?
Accidental Falls
1
2015
151
0.030
 Why?
Cell Death
1
2014
322
0.030
 Why?
Prospective Studies
1
2023
6195
0.020
 Why?
Blood Pressure
1
2018
1531
0.020
 Why?
Hydroxamic Acids
1
2012
80
0.020
 Why?
Health Policy
1
2014
330
0.020
 Why?
Dose-Response Relationship, Radiation
1
2011
127
0.020
 Why?
Histone Deacetylase Inhibitors
1
2012
197
0.020
 Why?
Androgens
1
2011
167
0.020
 Why?
Seizures
1
2012
337
0.020
 Why?
Polyethylene Glycols
1
2014
561
0.020
 Why?
Fatigue
1
2011
294
0.020
 Why?
Sex Factors
1
2014
1706
0.020
 Why?
Multivariate Analysis
1
2012
1422
0.020
 Why?
Positron-Emission Tomography
1
2009
260
0.020
 Why?
Radionuclide Imaging
1
2007
115
0.020
 Why?
Cell Membrane Permeability
1
2006
83
0.020
 Why?
Head and Neck Neoplasms
1
2008
427
0.010
 Why?
Cell Survival
1
2006
1014
0.010
 Why?
Ultrasonography
1
2006
635
0.010
 Why?
Incidence
1
2008
2314
0.010
 Why?
Flaig's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (382) concept(s)
_
Co-Authors Expand Description
See all (46) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)